FUNDING SIGNALS

Real Signals. Real Leads. Real Deals.

The only platform that turns real-time signals into your perfect leads

Know Who, Why, and When to reach out — instantly.

FundzWatch™ AI Scoring

10-25 leads daily

Real-time alerts

★★★★★

4.8/5 on G2• High Performer Fall 2025

Used by teams at LinkedIn, HubSpot & Oracle

🔒 app.fundz.net

TechCorp

📍 San Francisco👥 85

Post-Funding

⭐ Ideal Match

Just raised $40M Series B - high purchase intent window

Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy

Jun 04, 2020•over 5 years ago

Round Type

series b

Cambridge

Description

Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the completion of an extension to its Series B financing led by Columbus Venture Partners.

Company Information

Company

Immunomodulation

Location

Cambridge, Maryland, United States

About

A healthy immune system eliminates harmful foreign pathogens, while being tolerant of self-tissues and organs. When the immune system malfunctions, cells (T Cells) attack self-tissues and organs, causing autoimmune disease. Current autoimmune disease therapies suppress the immune system, helping to minimize these self-attacks, but also raise susceptibility to harmful foreign pathogens. Immunomodulation, the process in which the immune system reduces self-attacks while properly reacting to fight foreign pathogens, holds great potential for autoimmune disease therapies.

Company News

(1 articles)

Wed, 11 May 2022 07:00:00 GMT

Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases - PR Newswire

FundzWatch™ Score

Medium Activity